Biogen
Eisai, Biogen’s Leqembi reduces amyloid in Alzheimer’s, but safety concerns remain
Amid mounting concerns regarding the potential strain on healthcare infrastructure due to Leqembi, a drug for Alzheimer’s disease, Eisai and ...
Alnylam, Biogen show gene-silencing data for Alzheimer’s therapies
This week, Alnylam and Biogen took a significant step toward redefining the landscape of Alzheimer’s disease treatment by revealing promising ...
Roche, Biogen end patent dispute over Actemra biosimilar
Roche has swiftly resolved a patent infringement lawsuit it initiated against Biogen in July. The legal dispute centered around Biogen’s ...
Biogen faces renewed legal trouble over Aduhelm as investor lawsuit partially revived by court
For over a year, Biogen has been endeavoring to move past the controversies surrounding its drug Aduhelm and shift its ...
Biogen cuts jobs at Reata after $2.95 billion deal for kidney drug rights
A mere fortnight after the completion of Biogen’s acquisition of Reata Pharmaceuticals, the newly merged entity is taking a scalpel ...
Biogen hires Grogan as R&D head, aims to boost innovation and agility
Dr. Jane Grogan, who recently assumed her role as the head of research at Biogen, is eager to bring the ...
FDA Approves Biogen’s Biosimilar, Challenging Roche’s Actemra Dominance in the Market
Biogen has achieved a remarkable milestone while contemplating the future of its biosimilars division. The company proudly announced that its ...
FDA Approves Novartis’ Tyruko: Revolutionizing MS Treatment Landscape Amidst Legal Drama
Stepping onto the stage with a flourish, Novartis has secured a resounding victory against Biogen in the realm of pharmaceutical ...
Breaking: Biogen announces a massive layoff of 1,000 employees
Biogen, a pharmaceutical company, is undergoing a fresh wave of layoffs, with a targeted reduction of 1,000 positions following last ...
Sanofi Fails to Secure Reata in Bidding Battle Against Biogen Following Horizon Setback
Biogen’s pursuit of Reata, a rare disease company based in Texas, has unveiled a compelling narrative of corporate rivalry and ...
Biogen Outbids Competitor in $7.3 Billion Reata Pharmaceuticals Acquisition Duel
In a surprising turn of events, Biogen’s acquisition of Reata Pharmaceuticals for $7.3 billion raised eyebrows among industry observers last ...
FDA Approves Zurzuvae: A Game-Changer for Postpartum
Source – Biogen Biogen and Sage Therapeutics have received FDA approval for Zurzuvae (zuranolone) 50 mg, a breakthrough treatment for ...
Is Biogen giving up its biosims business to Samsung Bioepis?
During the first-quarter earnings call, CEO Chris Viehbacher discussed his plan to revitalize Biogen and emphasized the need to find ...
Biogen Buys Reata and Skyclarys for $7.3B, Cuts Jobs
During a quarterly earnings call, Biogen CEO Chris Viehbacher unexpectedly mentioned that the company had around $7.3 billion in cash. ...
Biogen anticipates 1,000 further layoffs by 2025 as it navigates a “transition”
Source – Biogen During the announcement of its first-quarter earnings, Biogen revealed its strategic decision to discontinue the development of ...
Eisai Unveils Lecanemab’s Alzheimer’s Breakthrough at AAIC 2023
Source – Eisai July 20, 2023 Biogen revealed the results of a comprehensive analysis of the Phase III Clarity AD ...
How will Medicare be affected by the cost of Leqembi from Eisai and Biogen? Sen. Sanders is curious
Senator Bernie Sanders (I-Vt.) is increasing his pressure on the US Department of Health and Human Services (HHS) regarding the ...
Eisai and Biogen Embark on Full Launch of Leqembi Following Alzheimer’s Approval
Source – Eisai On July 6, 2023, Eisai and Biogen received full approval from the FDA for their Alzheimer’s disease ...
